Ken Griffin Atara Biotherapeutics, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,400 shares of ATRA stock, worth $156,400. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,400

Previous 9,500 93.68%

Holding current value

$156,400

Previous $4,000 200.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.44 - $1.22 $2.75 Million - $7.62 Million	6,249,012 Added 2375.59%	6,512,063 $4.49 Million
Q4 2023 Feb 14, 2024	SELL	$0.23 - $1.74 $323,861 - $2.45 Million	-1,408,094 Reduced 84.26%	263,051 $134,000
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.31 $758,385 - $1.24 Million	537,862 Added 47.46%	1,671,145 $2.47 Million
Q2 2023 Aug 14, 2023	SELL	$1.5 - $3.04 $1.68 Million - $3.4 Million	-1,118,435 Reduced 49.67%	1,133,283 $1.82 Million
Q1 2023 May 15, 2023	BUY	$2.8 - $5.46 $2.39 Million - $4.66 Million	853,953 Added 61.09%	2,251,718 $6.53 Million

Q4 2022 Feb 14, 2023	BUY	$2.85 - $5.18 $3.89 Million - $7.08 Million	1,366,179 Added 4325.27%	1,397,765 $4.58 Million
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $8,099 - $24,810	2,842 Added 9.89%	31,586 $119,000
Q2 2022 Aug 15, 2022	SELL	$4.69 - $9.84 $497,135 - $1.04 Million	-105,999 Reduced 78.67%	28,744 $224,000
Q1 2022 May 16, 2022	BUY	$8.44 - $16.89 $557,099 - $1.11 Million	66,007 Added 96.03%	134,743 $1.25 Million
Q4 2021 Feb 14, 2022	BUY	$14.7 - $19.89 $531,757 - $719,500	36,174 Added 111.09%	68,736 $1.08 Million
Q3 2021 Nov 15, 2021	BUY	$11.99 - $17.9 $224,452 - $335,088	18,720 Added 135.24%	32,562 $583,000
Q2 2021 Aug 16, 2021	SELL	$12.89 - $16.58 $2.58 Million - $3.32 Million	-200,453 Reduced 93.54%	13,842 $215,000
Q1 2021 May 17, 2021	SELL	$14.0 - $20.72 $844,158 - $1.25 Million	-60,297 Reduced 21.96%	214,295 $3.08 Million
Q4 2020 Feb 16, 2021	SELL	$12.67 - $26.23 $2.35 Million - $4.87 Million	-185,535 Reduced 40.32%	274,592 $5.39 Million
Q3 2020 Nov 16, 2020	BUY	$11.92 - $15.87 $4.25 Million - $5.66 Million	356,762 Added 345.15%	460,127 $5.96 Million
Q2 2020 Aug 14, 2020	SELL	$7.53 - $14.93 $2.03 Million - $4.02 Million	-269,042 Reduced 72.24%	103,365 $1.51 Million
Q1 2020 May 15, 2020	BUY	$5.69 - $17.78 $662,833 - $2.07 Million	116,491 Added 45.52%	372,407 $3.17 Million
Q4 2019 Feb 14, 2020	SELL	$10.89 - $16.79 $4.22 Million - $6.5 Million	-387,431 Reduced 60.22%	255,916 $4.22 Million
Q3 2019 Nov 14, 2019	BUY	$12.03 - $19.94 $4.36 Million - $7.22 Million	362,267 Added 128.88%	643,347 $9.08 Million
Q2 2019 Aug 14, 2019	BUY	$19.05 - $41.04 $5.06 Million - $10.9 Million	265,763 Added 1735.09%	281,080 $5.65 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $41.74 $273,605 - $402,123	9,634 Added 169.52%	15,317 $0
Q2 2018 Aug 10, 2018	SELL	$35.15 - $51.45 $519,938 - $761,048	-14,792 Reduced 72.24%	5,683 $0
Q1 2018 May 11, 2018	BUY	$18.0 - $48.35 $368,550 - $989,966	20,475 New	20,475 $799,000

Others Institutions Holding ATRA

# of Institutions

Shares Held

85M

Call Options Held

18.4K

Put Options Held

51.3K

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $802M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account